Tuesday, November 17, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
How to earnPaparazzi InkHolder perksLeaderboardAssignmentsContestsLeagueCity
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsCity LeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundToken utilityRobinhood Chain launchesRobinhood Chain projectsPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 55

Novartis' Cosentyx wins FDA nod as first anti-IL-17 biologic for PMR

Novartis just scored FDA approval for Cosentyx (secukinumab) 150 mg in polymyalgia rheumatica, making it the first and only anti-IL-17 biologic cleared for the disease. It's the 11th US indication for the drug, and it hands patients an alternative to the long steroid courses that dominate PMR care.

By the Paparazzi desk November 16, 2026 · 4:00 PM · finance.yahoo.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: finance.yahoo.com.
  • The source published it on Nov 16, 2026 at 4:00 PM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The FDA approved Cosentyx at 150 mg for adults with polymyalgia rheumatica who have responded poorly to corticosteroids or can't handle tapering off them. Novartis announced the green light on November 17, 2026, from Basel. It's the first and only anti-IL-17 biologic approved for PMR, a condition that mostly hits adults over 50.

The Phase III REPLENISH trial backed the filing: secukinumab doubled sustained remission rates and showed steroid-sparing effects compared with placebo. "In the Phase III REPLENISH trial, secukinumab doubled the likelihood of sustained remission while helping patients taper off steroids, which should be the goal of PMR treatment," said Prof. John Stone, professor of medicine at Harvard Medical School and Massachusetts General Hospital, and global principal investigator for the trial.

Sponsored

Roughly 966,000 people in the US live with PMR, which brings acute pain and stiffness in the shoulders, neck and hips. Steroids are the standard treatment, but up to 40% of patients relapse within the first year, and long-term use raises the risk of osteoporosis, cardiovascular disease and diabetes. "For years, patients have had too few treatment options," said Seth Ginsberg, co-founder and president of the Global Healthy Living Foundation and CreakyJoints.

This is the 11th US indication for Cosentyx, which Novartis says rests on more than a decade of clinical experience across immune-mediated diseases. The PMR indication is already approved in the EU, with further regulatory reviews still in play, including in Japan.

TopicsNovartis · Cosentyx · secukinumab · FDA · REPLENISH trial · John Stone · Global Healthy Living Foundation · Seth Ginsberg

Share

Source: finance.yahoo.com

Written by AI from verified reporting.

More stories

  • Health & science 3 hours ago · casrai.org · 0 views
    FDA greenlights giredestrant-everolimus duo for ESR1-mutated breast cancer
  • Health & science 4 hours ago · nbcnews.com · Caught by @nina.anggraini29 · 0 views
    Measles Is Endemic Again as the U.S. Loses Its Elimination Status
  • Health & science 4 hours ago · aol.com · 1 view
    FDA Clears FoundationOne Liquid CDx as First Companion Test for WILSERDLY Combo
  • Health & science 7 hours ago · statnews.com · 1 view
    FDA approves Roche's Wilserdly for resistant breast cancer
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.